[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644695":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":32,"responsibleParty":43,"collaborators":45,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":32,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":32,"enrollmentInfo":64,"targetDuration":32,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":80,"whyStopped":32,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":32},{"fullName":5,"class":6},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Endovascular Therapy Plus Best Medical Management","EXPERIMENTAL","Participants assigned to this group will receive endovascular therapy in addition to best medical management. Endovascular therapy may include stent retriever thrombectomy, direct aspiration thrombectomy, or combined techniques, according to the vascular anatomy, thrombus characteristics, and operator judgment. Eligible patients may receive intravenous thrombolysis before endovascular therapy according to standard clinical guidelines.",[13],"Procedure: Endovascular Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Best Medical Management Alone","ACTIVE_COMPARATOR","Participants assigned to this group will receive best medical management according to current stroke guidelines. Eligible patients within the intravenous thrombolysis time window may receive standard-dose intravenous thrombolysis. Other medical treatment may include antithrombotic therapy, risk factor management, blood pressure management, and supportive stroke care according to local and guideline-based practice.",[19],"Other: Best Medical Management",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Endovascular Therapy","Endovascular therapy consists of mechanical thrombectomy using stent retriever, direct aspiration, or combined techniques with the goal of achieving rapid and effective reperfusion of the occluded basilar artery.",[9],[27],"Mechanical thrombectomy",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Best Medical Management","Best medical management includes intravenous thrombolysis when eligible, antithrombotic therapy, standard stroke unit care, management of vascular risk factors, blood pressure control, and supportive care according to current clinical guidelines.",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Wei Hu, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Chunrong Tao, PhD","CONTACT","+8662284079","chunrongtao@126.com",{"type":44,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[46,48,50,53],{"name":47,"class":6},"Dalian Municipal Central Hospital",{"name":49,"class":6},"Linyi People's Hospital",{"name":51,"class":52},"Fujian Zhangzhou hospital","UNKNOWN",{"name":54,"class":52},"Shanghai Minhang District Central Hospital","100644695","endovascular-therapy-for-acute-basilar-artery-occlusion-with-large-ischemic-core-100644695",false,"NCT07672795","Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core","Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke.\n* Basilar artery occlusion confirmed by CTA, MRA, or DSA.\n* Posterior circulation ASPECTS \\\u003C7 on CT, CTA source images, or MRI-DWI.\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Written informed consent obtained from the patient or legally authorized representative.\n* Baseline NIHSS score ≥6 before randomization.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score ≥3.\n* Pregnancy or lactation.\n* Known allergy to contrast agents or nickel-titanium alloy.\n* Current participation in another clinical trial.\n* Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy.\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \\>1.7.\n* Blood glucose \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL, platelet count \\\u003C50 × 10\\^9\u002FL, or hematocrit \\\u003C25%.\n* Life expectancy less than 1 year.\n* Inability to complete 90-day follow-up.\n* Definite history of cerebral vasculitis.\n* Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment.\n* Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \\\u003C5 mm on MRI.\n* Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment.\n* Intracranial tumor, except for small meningioma.","ALL","18 Years",{"count":65,"type":66},256,"ESTIMATED","INTERVENTIONAL",[69],"NA","Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.\n\nThis prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \\\u003C7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.",[72,73,74],"Acute Ischemic Stroke","Basilar Artery Occlusion","Large Ischemic Core",[76,77,27,78,79],"Basilar artery occlusion","Endovascular therapy","Posterior circulation stroke","Large ischemic core","NOT_YET_RECRUITING","2026-06-30",{"date":83,"type":84},"2026-07-02","ACTUAL",{"date":86,"type":66},"2026-08-01",{"date":88,"type":66},"2029-12-31",{"name":5,"class":6}]